INTRODUCTION
Pharmacogenetic research is aimed at relating genetic variation to interindividual differences in drug response. An important prerequisite for a pharmacogenetic study is a thorough knowledge of DNA sequence variation in a candidate gene or set of candidate genes. 1 Variants with influence on drug response can have frequencies ranging from common to extremely rare, 2 influencing the chances of the success of a pharmacogenetic study.
The investigation of common variants can be economized by concentrating on variants that optimally capture the haplotype diversity of a given gene (so-called haplotype-tagging SNPs, htSNPs), making use of the nonrandom association between SNPs in proximity to one another (so-called linkage disequilibrium). The number of SNPs reported in public databases currently exceeds 9.8 million (NCBI dbSNP Build 121), and we are on the way to understanding the organization of SNPs within haplotypes and systematically defining htSNPs for candidate genes. A major aim of the human HapMap project is to identify htSNPs on a genome wide scale, based on SNPs currently reported in public databases.
Notwithstanding the role of htSNPs in understanding the contribution of common variants to drug response, their use in identifying the contribution of rare variants will be limited, because rare variants will be hard to represent with htSNPs. It has been shown that rare variants are more likely to have potential functional significance. [4] [5] [6] Lowfrequency functional variants in particular may account for severe adverse reactions to medication. Although these severe adverse reactions are relatively rare, at least 100 000 deaths per year in the United States alone are attributed to adverse reactions to prescription drugs. 7 Unfortunately, SNP databases show a strong under-representation of rare variants. 5 This is not surprising since the chance of detecting a variant on a limited number of chromosomes correlates with its population frequency. Consequently, focused resequencing in larger samples of individuals is necessary to systematically identify low-frequency variants.
Previous large-scale resequencing studies 4, 5, 8, 9 found lower nucleotide diversity for coding regions compared to noncoding regions and decreased allele frequency for coding SNPs. These findings can be explained by the influence of purifying selection on nucleotide diversity in the human genome. Purifying selection is also assumed to be an important force accounting for sequence conservation between species. However, no study so far investigated to what extent interspecies sequence conservation of both coding and noncoding genomic regions is reflected in nucleotide diversity.
Our study employed a resequencing approach in 111 candidate genes for variation in drug response for drugs that are active in the CNS. Genes encoding possible targets for CNS active drugs or elements of their associated pathways were preferentially selected. Among them, for example, were 12 enzymes, 20 ion channels and 47 genes involved in signal transduction, including 19 G-protein coupled receptors. Some of the genes were selected from positional candidate genes for neuropsychiatric disorders because of their location in chromosomal regions showing confirmed linkage to schizophrenia and bipolar disorder. The underlying assumption here was that genes contributing to the risk of disease would also be excellent candidates as genes with an influence on drug response. Sequencing was performed on an average sample of 170 chromosomes for each gene locus.
RESULTS

Nucleotide Diversity of Sequenced Regions
Nearly 295 kb of genomic sequence from 111 gene loci have been resequenced in an average sample of 170 chromosomes for each gene locus. More than 292 kb of the sequencing results could be aligned to the human genome assembly (build 34), including 112.6 kb of coding regions and 179.6 kb of flanking noncoding regions. Within the aligned fragments, a total of 729 biallelic SNPs were identified.
Variability of genomic regions can be assessed by estimating the three diversity parameters nucleotide heterozygosity p, level of nucleotide polymorphism y and Tajima's D (see Materials and Methods for details). The analysis of nucleotide diversity for coding and noncoding regions in our data set (Table 1) showed estimates of p, y and Tajima's D, which were comparable with estimates from samples of European or European American origin obtained elsewhere. 4, [8] [9] [10] The restriction of the analysis to nonsynonymous SNPs and coding regions showed further decreased estimates for p NS , y NS and Tajima's D NS . These estimates were even lower for genomic regions coding for Pfam 11 domains or PROSITE 12 sequence motifs (Table 1 ). In comparison, genomic regions encoding none of these conserved sequence patterns displayed both a higher nucleotide heterozygosity p NS and a higher level of nucleotide polymorphism y NS .
In the following we analyzed nucleotide diversity parameters for noncoding regions, categorizing them according to their interspecies sequence conservation level. Based on For each sequence category the number of base pairs resequenced, the number of SNPs identified, the estimated nucleotide heterozygosity p, the level of nucleotide polymorphism y and Tajima's D value are given. Sequence annotations were transferred from the Ensembl genome database to the sequenced fragments. Noncoding regions were categorized as hcons (both): highly conserved between human and rodents (both mouse and rat); hcons (either): highly conserved comparing to either mouse or rat or both; cons (both): conserved to both mouse and rat; cons (either): conserved to either mouse or rat or both. Alignments to known protein sequence pattern (Pfam or PROSITE) were applied for categorization of coding regions.
Variability in candidate genes for drug response Y Freudenberg-Hua et al BLASTZ 13 genome-genome alignments, the Ensembl database 14 annotates the genomic regions as either nonconserved, conserved or highly conserved between human and rodents (mouse or rat). For noncoding regions annotated as conserved between human and rodents, we did not find a nucleotide diversity pattern, which was clearly different from the overall pattern of noncoding regions. However, we observed low estimates of p and y in regions annotated as highly conserved between human and rodents (Table 1) . Moreover, we observed negative values of Tajima's D for highly conserved noncoding regions, which further suggests that selection shapes nucleotide diversity in these regions. Among the presumably neutrally evolving remaining noncoding sequence regions, we observed a positive Tajima's D value in our data set, which may be attributed to population demographic events.
Furthermore, we observed a high variability among different gene loci ( Table 3 . When categorizing nonsynonymous SNPs with respect to their location in a conserved protein sequence pattern, that is, in a Pfam domain or PROSITE motif, the nonsynonymous to synonymous ratio was consistent with the assumption of increased selective pressure acting upon conserved protein patterns. The nonsynonymous/synonymous ratio of SNPs was 0.66 in PROSITE motifs and 0.80 in Pfam domains, whereas it was 1.22 in regions outside these patterns.
To assess the influence of purifying selection on different categories of SNPs, we then compared the average minor allele frequency (MAF) ( Figure 1 ). As described earlier, 5 MAF differed significantly between synonymous SNPs (MAF ¼ 12.0%, n ¼ 143), conservative amino-acid alterations (MAF ¼ 8.3%, n ¼ 105) and radical amino-acid alterations (MAF ¼ 4.7%, n ¼ 26) (P ¼ 0.001, Kruskal-Wallis H test). When analyzing the 453 noncoding SNPs, we found MAF of SNPs located in regions annotated as highly conserved (either mouse or rat or both) (MAF ¼ 11.2%, n ¼ 119) significantly lower than MAF of noncoding SNPs not located in such highly conserved regions (MAF ¼ 14.0%, n ¼ 334) (P ¼ 0.001, two-sided Mann-Whitney U test). No significant difference was observed between SNPs in regions classified as conserved (MAF ¼ 13.1%, n ¼ 413) and nonconserved
SNP Representation in Public Databases
A previous study has evaluated SNP coverage of the public databases in a subset of 65 of the genes included in the set of gene loci analyzed here. 5 This evaluation was based on dbSNP build 112, released on 21 March 2003, containing 3 741 182 human SNPs. At that time, 159 (41%) of a total of 388 identified SNPs were known as polymorphic sites to dbSNP, the coverage rate was high (80%) for highly frequent variants (MAFZ20%) and only 20% for rare variants (MAFo5% except singletons). Since this previous evaluation, the dbSNP content has increased by more than 6 million new SNPs to a total of 9 856 125 SNPs. In a first step, we evaluated the improvement of coverage of dbSNP (build 121, released on 1 June 2004) based on the same set of variants used in the previous evaluation. When disregarding database submissions resulting from the present study, among the subset of variants analyzed previously on dbSNP build 112, we found a coverage of 97% for highly frequent SNPs (MAFZ20%) and 32% for rare variants (MAFo5% except singletons). Among the total of 729 SNPs analyzed in the present study, the database coverage was 94% for high frequency SNPs, 27% for rare SNPs except singletons and 25% (n ¼ 7) for the 28 radical variants.
Identification of htSNPs
More than 80% of haplotype diversity was covered by common haplotypes (population frequency 45%) for 98 loci, whereas for 13 loci less than 80% of total estimated haplotype diversity could be represented by htSNPs ( Table  2 ). The potential benefit and problems in the application of gene-based htSNPs 15 for association studies may be best illustrated by the comparison of the CRHR1 and NOTCH4 loci. The gene CRHR1 has 12 exons spanning about 28 kb of genomic region. We identified 14 SNPs, among them 13 common SNPs, but only four common haplotypes with an estimated population frequency of 52, 15, 11, and 8%, respectively. In this case, only three htSNPs are required to capture common haplotype diversity accounting for 86% of total haplotype diversity. On the other hand, the gene NOTCH4 has 30 exons stretching over about 29 kb of genomic region with a total of 60 SNPs and 30 common SNPs with MAF Z5% among them. NOTCH4 shows three common haplotypes with population frequencies of 13, 8, and 6%, respectively. This means that only 27% of total haplotype diversity is covered by common haplotypes, and consequently, the use of gene-based htSNPs in an association study of NOTCH4 is likely to miss an association of a phenotypic trait with a single common SNP, if present.
The average number of SNPs per gene was 6.7 (median 5, range 0-60), the average number of common SNPs per gene was 3.2 (median 2, range 0-30), and the average number of htSNPs per gene was 1.6 (median 2, range 0-5). The number of htSNPs capturing common haplotype diversity for all resequenced gene loci was 177, which is about half of the For each locus the respective HUGO identifier (if existent), the LocusLink key, the number of resequenced exons, the number of base pairs aligned to the Human Genome Assembly (NCBI34), the number of SNPs identified (total and common SNPs as well as htSNPs at loci where common haplotype diversity accounts for more than 80% of total haplotype diversity) as well as the estimates of nucleotide heterozygosity p and the level of nucleotide polymorphism y are shown. number of common SNPs (MAFZ5%, n ¼ 347). However, the use of gene-based htSNPs requires that a high fraction of total gene-based haplotype diversity is covered by common haplotypes. For the 98 gene loci, for which common haplotypes covered more than 80% of haplotype diversity, the total number of htSNPs was 141, which is 61% of their 230 common SNPs (MAFZ5%). The average ratio between the numbers of htSNPs to common SNPs at these 98 loci was 73%. This htSNPs to common SNPs ratio was found to be inversely correlated with nucleotide heterozygosity p among the investigated gene loci (Spearman's r ¼ À0.276, P ¼ 0.021) and level of nucleotide polymorphism y (Spearman's r ¼ À0.282, P ¼ 0.018). This illustrates that htSNPs are more efficient at those loci that are more polymorphic both with regard to the density and to the frequency of SNPs. At the 13 gene loci, where common haplotype diversity accounts for less than 80% of total haplotype diversity, recombination and gene conversion may have played a greater role in shaping the observed haplotype diversity. A more detailed analysis, involving the partitioning of these loci into discrete haplotype blocks, will be necessary to investigate the properties of htSNPs at these loci.
DISCUSSION
Our study describes sequence variability for a set of 111 genes whose gene products may be implicated in variations in drug response. Low population frequency was observed for nonsynonymous SNPs and, in particular, for radical SNPs. These findings illustrate that those variants that are more likely to be functionally relevant are observed at lower frequencies in the population. An explanation for this finding may be that natural selection acts against these functionally important variants, and thereby prevents a higher allele frequency. This implies that functionally important variants are mildly disadvantageous in most cases. If located in a drug target or a protein affecting pharmacokinetics, these functional variants may be responsible for adverse drug effects or may influence drug efficacy. Since functionally relevant variants are overrepresented among rare variants, pharmacogenetic analyses should not be restricted to a small set of common variants, but should also include low-frequency variants. For membrane transporter genes, Leabman et al 4 showed that nucleotide diversity was lower in predicted transmembrane domains than in less evolutionarily conserved loop regions. In our study, we found that nonsynonymous nucleotide diversity is generally lower within Pfam protein domains or PROSITE motifs than diversity outside these regions. This finding is consistent with stronger constraints on those parts of coding regions, which are particularly conserved between species. The idea that variation in noncoding regulatory regions might influence drug response has previously been addressed from a theoretical perspective 1 and has been illustrated by the finding that a promoter variant of the gene ALOX5 in the leukotriene pathway affects drug efficacy of ALOX5 inhibitors in patients with asthma. 16 Our observation of a decreased MAF for SNPs in noncoding regions conserved between human and rodents compared to regions with low or no conservation may partially result from increased selective pressure acting upon gene regulatory elements, which are harboured within conserved regions. As a consequence, pharmacogenetic studies investigating noncoding variants should give preference to those located in highly conserved regions.
For high-frequency variants (MAFZ20%), the coverage rate in the public database dbSNP nears completion (94%). In contrast, rare variants remain under-represented, with a coverage of only approximately 27% for nonsingleton variants with MAF less than 5%. Large-scale resequencing efforts are necessary to identify rare variants, requiring a sufficiently large number of individuals. In addition, candidate gene sequencing in a smaller set of individuals showing a distinct phenotype in drug response may detect those rare variants that otherwise would remain undetected.
Among the identified variants were two nonsense mutations (Table 2) , which are unlikely to encode a functional protein. These mutations are located in the corticotropin releasing factor receptor 2 precursor (CRHR2) and the Gprotein-coupled receptor 58 (GPR58).
Among the 131 identified missense variants, 26 were of a radical nature. These variants may significantly alter the function of the respective protein, although this can only be a matter of speculation at the present time. For example, in the alpha1b-adrenergic receptor (a1bR, ADRA1B), we observed a valine to glycin exchange at an evolutionary conserved position in the first transmembrane in two independent healthy individuals. In the photoreceptor protein of rod cells, rhodopsin, which serves as a model for the G protein-coupled receptor superfamily, it has been shown that the reciprocal exchange, Gly51Val, is associated with autosomal dominant retinitis pigmentosa due to missfolding of the protein and altered function. 17, 18 Another example is the Gly140Arg variant of the vesicular amine transporter 1 (VMAT1, SLC18A1), which was also observed as a singleton in another large-scale resequencing study, 4 confirming the true nature of this rare variant. VMAT1 is responsible for the peripheral vesicular storage and restorage of released catecholamines, serotonin and histamine. 19 This exchange is located in a highly conserved N-myristoylation site (determined with PROSITE 12 ), which Previous studies have discussed the advantages of htSNPs. 15, 20 Among 98 of the 111 resequenced gene loci, the use of htSNPs would reduce by about a third the genotyping effort required to capture more than 80% of total haplotype diversity of coding regions for the European population. Moreover, our analysis showed that gene-based htSNPs for the coding and flanking regions of the resequenced genes would particularly reduce genotyping effort required in mapping studies at loci, which are more polymorphic and show high common haplotype diversity. The use of htSNPs, however, does not take into account rare haplotypes, which, for some genes, account for most of total gene-based haplotype diversity, as exemplified in an extreme case by the NOTCH4 gene. Furthermore, when more noncoding regions were resequenced, the number of gene loci in which common haplotypes account for a low fraction of total haplotype diversity, is likely to increase. 21 A limitation of our study is that we only generated data for a European population. As it is known that linkage disequilibrium characteristics can differ substantially among populations from different regions of the world, 22 additional effort to characterize htSNPs has to be undertaken if pharmacogenetic studies with this set of genes are performed in non-European populations. Furthermore, the rare variants identified in the European population may not be present in non-European populations and vice versa.
In conclusion, we investigated genetic variability in a set of 111 candidate genes using a systematic resequencing approach. We identified a large number of functionally important rare variants, as inferred from signatures of purifying selection. Within noncoding regions, we observed an excess of rare variants in sequences highly conserved between human and rodents. We further confirmed that gene-based htSNPs are most efficient in covering common haplotype diversity at gene loci that are more polymorphic with regard to both the density and the frequency of SNPs.
MATERIALS AND METHODS
DNA Samples
DNA samples were taken from a DNA bank representative of the European population. The characteristics of this DNA bank have been described in detail elsewhere. 5 In summary, the bank contains DNA from 96 unrelated healthy individuals and the proportion of individuals included from each European country corresponds to current population sizes (Supplementary Table 2 ). The approval of the ethics committee of the Medical Faculty of the University Bonn was obtained prior to sample collection and written informed consent was obtained from each participating individual.
The probability P of detecting a given variant, v, with a minimal population frequency, f, is given by P(v) ¼ 1À(1Àf) 2N , where N is the number of individuals. Between 47 and 96 individuals were resequenced at the different gene loci investigated in the present study. A variant with a population frequency of 1% is detected with a probability of B85% in a sample of 96 individuals.
Resequencing of a population sample of size 47 individuals results in a probability of B61% for detecting a variant with a frequency of 1%.
Selection of Candidate Genes
Genomic sequences of candidate genes were obtained from the clone sequence entries of the NCBI GenBank database. 23 Expression information was obtained from NCBI UniGene Clusters and priority was given to genes expressed in the central nervous system. 23 For genes without contig annotations, gene models were identified aligning the respective mRNA or cDNA sequences to genomic clones using BLAST 24 (Supplementary Table 1 ) Only candidate genes for which genomic sequence data upstream and downstream of all known exons are available were selected.
PCR Amplification of Coding Regions and DNA Sequencing
According to the respective annotation of coding sequence parts, primers were designed either using the Primer3 Program 25 or manually. PCR fragments contained at least 50 bases of the 5 0 and 3 0 flanking regions for each exon. Double-strand DNA sequencing using the chain-termination method 26 was performed commercially (AGOWA, Berlin, Germany; BGI LifeScience, Beijing, PR China; Medigenomix, Munich, Germany, and SEQLAB, Göttingen, Germany). Internal sequencing primers were used to increase reaction specificity.
Data Analysis and Software
Primary evaluation of sequencing traces was performed with software packages Phred, 27 Phrap, 27 Polyphred 28 and Consed 29 from Washington University. All SNPs detected by Polyphred were checked by a human expert. Inconsistencies between forward and reverse reads in genotype outputs were manually edited. For about 10% of all amplified exons, no sequencing data were obtained due to either sequencing failure or low trace quality. Consensus sequences of all successfully resequenced exons were submitted to dbSNP. Consensus sequences of resequenced fragments were aligned to the human genome using Megablast, 30 allowing for the annotation of own experimental data according to human genome annotations from the Ensembl database (Version 19.34).
14 Megablast implements a heuristic string comparison algorithm, which can be run locally with high number of sequences, but possibly misses a small fraction of actually matching parts of two sequences.
Categorization of SNPs
According to annotations provided by the database Ensembl, 14 genomic regions were categorized into coding and 
Estimation of the Population Mutation Parameter
The population mutation parameter was estimated using two different strategies: nucleotide heterozygosity p, which is the number of nucleotide differences per site between two randomly selected sequences from a population, and level of nucleotide polymorphism y, which is the proportion of nucleotide sites that are expected to be polymorphic in a population sample, corrected for the sample size. 32 Furthermore, Tajima's D statistic 33 was calculated for different sequence categories. Tajima's D statistic is the normalized difference between p and y and can detect departures from standard neutral evolution models. A negative Tajima's D value indicates an excess of rare alleles, whereas a positive value indicates an excess of intermediate frequency variants.
